Taking A GLP-1 In Perimenopause, When Your Hormones Are Already Moving

A large proportion of women starting GLP-1 medication are somewhere in the perimenopausal transition, which is not a coincidence: this is exactly the life stage when body composition shifts, weight becomes harder to move, and the strategies that used to work stop working.

It also means two significant physiological processes are running at once, with overlapping symptoms. Untangling them is the whole task.

Which symptom belongs to which?

Fatigue, disrupted sleep, low mood, brain fog and changes in appetite appear on both lists, which is why this is genuinely difficult rather than merely confusing.

Some rough guidance. Nausea, constipation, reflux and early fullness are far more likely to be the medication, particularly if they track your dosing cycle. Hot flushes, night sweats, vaginal dryness, joint aching and cycle changes point towards perimenopause. Fatigue and mood belong to both and need a longer look.

The timing test

The single most useful discriminator is whether a symptom tracks your dose. Medication side effects tend to cluster in the days after an injection and ease later in the cycle. Perimenopausal symptoms tend to track your menstrual cycle, or to have no weekly pattern at all.

This is one of the few genuinely diagnostic things you can do at home, and it requires only that you write symptoms down against dates for two or three cycles.

Why muscle matters even more here

Muscle mass declines with age, and the decline accelerates through the menopausal transition as oestrogen falls. Bone density follows a similar course.

Layering rapid weight loss on top of that is where the risk sits. The two protections are the same as ever and matter more: resistance training two to three times a week, and a protein intake that rises during a deficit — see protecting muscle on a GLP-1. Requirements increase with age because ageing muscle responds less strongly to the same dose of protein, so around 40g per meal is a reasonable target after sixty.

Can you take HRT and a GLP-1 together?

They are not mutually exclusive, and many women take both. HRT addresses vasomotor symptoms, sleep, mood and bone density; a GLP-1 addresses weight and metabolic health. They are treating different things.

What matters is that whoever prescribes each knows about the other. Transdermal HRT — patches and gels — bypasses the digestive system, which sidesteps any absorption question. This is worth raising directly rather than assuming your notes have joined it up.

The bone conversation

Rapid weight loss reduces bone density, and perimenopause reduces it independently. Together they warrant a specific discussion, particularly if you have other risk factors: a family history of fracture, a low BMI to begin with, smoking, or long-term steroid use.

Ask whether a DEXA scan is appropriate. Resistance and impact training protect bone as well as muscle, which is another reason the lifting is not optional.

Keeping the two threads separate

Practically, this comes down to a record with dates in it: symptoms, dose days, and where you are in your cycle. It is the only way to answer “is this the medication or is this perimenopause?” with anything better than a shrug.

A GLP-1 companion app such as Zenday App is useful here for one narrow reason: it anchors symptoms to dose day, which is the axis that separates the two. Take that record to your appointment — it turns “I've been feeling awful” into something a clinician can act on. Our perimenopause timeline covers the other half of the picture.